A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as baricitinib in participants with systemic lupus erythematosus.
Inclusion Criteria:
Exclusion Criteria:
Ciudad Autonoma de Buenos Aire, C1204AAD, Argentina
Ciudad Autonoma de Buenos Aire, C1417EYG, Argentina
San Juan, J5402DIL, Argentina
San Miguel de Tucumán, T4000AXL, Argentina
San Miguel de Tucumán, T4000BRD, Argentina
Graz, 8036, Austria
Vienna, 1090, Austria
Vienna, 1130, Austria
Bordeaux, 33076, France
Marseille, 13003, France
Pessac, 33604, France
Strasbourg, 67098, France
Asahikawa, 070-8644, Japan
Chūōku, 104-8560, Japan
Fukuoka, 810-8563, Japan
Hamamatsu, 430-8558, Japan
Itabashi-ku, 173-8610, Japan
Kawagoe, 350-8550, Japan
Kita-gun, 761-0793, Japan
Kitakyushu, 807-8556, Japan
Meguro-ku, 153-8515, Japan
Nagasaki, 852-8501, Japan
Ōmura, 856-8562, Japan
Sapporo, 060-8648, Japan
Sasebo, 857-1195, Japan
Sendai, 980-8574, Japan
Guadalajara, 44650, Mexico
Guadalajara, 44690, Mexico
Mexico City, 06700, Mexico
Zapopan, 45030, Mexico
Bydgoszcz, 85-168, Poland
Bytom, 41-902, Poland
Elblag, 82-300, Poland
Gdansk, 80-546, Poland
Nadarzyn, 05-830, Poland
Świdnik, 21-040, Poland
Brasov, 500283, Romania
Bucharest, 011172, Romania
Galati, 800587, Romania
Târgu Mureş, 540136, Romania
Gwangju, 61469, South Korea
Incheon, 22332, South Korea
Seoul, 02447, South Korea
Seoul, 03080, South Korea
Suwon, 16499, South Korea
Badalona, 08916, Spain
Barcelona, 08035, Spain
Madrid, 28007, Spain
Madrid, 28041, Spain
Vigo, 36200, Spain
Kaohsiung City, 83301, Taiwan
Taichung, 40201, Taiwan
Taichung, 40447, Taiwan